PE20250401A1 - Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias - Google Patents
Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitariasInfo
- Publication number
- PE20250401A1 PE20250401A1 PE2024003046A PE2024003046A PE20250401A1 PE 20250401 A1 PE20250401 A1 PE 20250401A1 PE 2024003046 A PE2024003046 A PE 2024003046A PE 2024003046 A PE2024003046 A PE 2024003046A PE 20250401 A1 PE20250401 A1 PE 20250401A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- formula
- pyrazolo
- auto
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021120406 | 2021-09-24 | ||
| CN2022089033 | 2022-04-25 | ||
| PCT/EP2022/076306 WO2023046806A1 (en) | 2021-09-24 | 2022-09-22 | Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250401A1 true PE20250401A1 (es) | 2025-02-11 |
Family
ID=83688579
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024003046A PE20250401A1 (es) | 2021-09-24 | 2022-09-22 | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias |
| PE2024000482A PE20240815A1 (es) | 2021-09-24 | 2022-09-22 | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000482A PE20240815A1 (es) | 2021-09-24 | 2022-09-22 | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias |
Country Status (16)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026515029A (ja) * | 2023-04-28 | 2026-05-13 | 成都思倍博医▲薬▼科技有限公司 | オキソピリド脂肪族環又は脂肪族複素環構造を含む化合物及びその医学的使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9643967B2 (en) * | 2013-12-13 | 2017-05-09 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors |
| EP4059934B1 (en) | 2016-09-09 | 2026-07-29 | Novartis AG | Compounds and compositions as inhibitors of endosomal toll-like receptors |
| JP2021507889A (ja) * | 2017-12-22 | 2021-02-25 | ノバルティス アーゲー | ピラゾロピペリジン誘導体の新規な使用 |
| WO2019220390A1 (en) | 2018-05-18 | 2019-11-21 | Novartis Ag | Crystalline forms of a tlr7/tlr8 inhibitor |
| CN112752755A (zh) * | 2018-09-27 | 2021-05-04 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的杂环基化合物 |
| JP2023533807A (ja) * | 2020-07-14 | 2023-08-04 | エフ. ホフマン-ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 |
-
2022
- 2022-09-22 PE PE2024003046A patent/PE20250401A1/es unknown
- 2022-09-22 CR CR20240134A patent/CR20240134A/es unknown
- 2022-09-22 CA CA3228485A patent/CA3228485A1/en active Pending
- 2022-09-22 MX MX2024003444A patent/MX2024003444A/es unknown
- 2022-09-22 KR KR1020247009335A patent/KR20240065092A/ko active Pending
- 2022-09-22 AU AU2022351495A patent/AU2022351495A1/en active Pending
- 2022-09-22 PE PE2024000482A patent/PE20240815A1/es unknown
- 2022-09-22 JP JP2024518351A patent/JP2024534567A/ja active Pending
- 2022-09-22 EP EP22786353.7A patent/EP4405051B1/en active Active
- 2022-09-22 IL IL310443A patent/IL310443A/en unknown
- 2022-09-22 CN CN202280063841.XA patent/CN118076604A/zh active Pending
- 2022-09-22 WO PCT/EP2022/076306 patent/WO2023046806A1/en not_active Ceased
- 2022-09-22 AR ARP220102558A patent/AR127126A1/es unknown
- 2022-09-23 TW TW111136043A patent/TW202328129A/zh unknown
-
2024
- 2024-03-15 US US18/606,123 patent/US20240360126A1/en active Pending
- 2024-03-18 CL CL2024000791A patent/CL2024000791A1/es unknown
- 2024-03-19 CO CONC2024/0003401A patent/CO2024003401A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240065092A (ko) | 2024-05-14 |
| EP4405051A1 (en) | 2024-07-31 |
| TW202328129A (zh) | 2023-07-16 |
| CL2024000791A1 (es) | 2024-09-06 |
| AU2022351495A1 (en) | 2024-02-01 |
| PE20240815A1 (es) | 2024-04-18 |
| CN118076604A (zh) | 2024-05-24 |
| CO2024003401A2 (es) | 2024-04-29 |
| JP2024534567A (ja) | 2024-09-20 |
| AR127126A1 (es) | 2023-12-20 |
| MX2024003444A (es) | 2024-04-03 |
| EP4405051B1 (en) | 2026-07-15 |
| US20240360126A1 (en) | 2024-10-31 |
| WO2023046806A1 (en) | 2023-03-30 |
| CR20240134A (es) | 2024-05-07 |
| CA3228485A1 (en) | 2023-03-30 |
| IL310443A (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2883751C (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| PE20242113A1 (es) | Compuestos de quinolina como inhibidores de kras | |
| EA200702445A1 (ru) | Соединения тиазола и способы их применения | |
| EA200601281A1 (ru) | Азабензофуранзамещенные тиомочевины; ингибиторы репликации вирусов | |
| EA200602130A1 (ru) | Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов | |
| SV2002000504A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| PE20030823A1 (es) | Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo | |
| SG11201809859VA (en) | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | |
| BRPI0510414A (pt) | uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos | |
| EA200500846A1 (ru) | Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации | |
| CO2023004420A2 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| AR040673A1 (es) | Inhibidores micobacterianos, composicion farmaceutica y proceso de preparacion del compuesto | |
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| ES2701087T3 (es) | Derivados de [1,2,4]-triazolo-[1,5-a]-pirimidina como inhibidores del proteasoma de protozoarios para el tratamiento de enfermedades parasitarias tales como leishmaniasis | |
| MX2021012223A (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria. | |
| MX2019013383A (es) | Agente terapeutico para la demencia que combina derivado de pirazoloquinolina y memantina. | |
| MX2025012439A (es) | Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion | |
| PH12020551772A1 (en) | Oxo-substituted compound | |
| KR20120048697A (ko) | 폭스바이러스 감염의 치료 방법 | |
| NZ761680A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| CA2487252A1 (en) | Esters in position 20 of camptothecins | |
| ES2158223T3 (es) | Utilizacion de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de las enfermedades asociadas con la presencia de oxigeno activo y de radicales libres. |